References
- Onglyza [package insert]Princeton, NJ/Wilmington, DEBristol-Myers Squibb Company/AstraZeneca Pharmaceuticals LP72009
- PathakRBridgemanMBDipeptidyl peptidase-4 (DPP-4) inhibitors in the management of diabetesP T201035950951320975810
- DresserGKSpenceJDBaileyDGPharmacokinetic-pharmaco-dynamic consequences and clinical relevance of cytochrome P450 3A4 inhibitionClin Pharmacokinet2000381415710668858
- ScheenAJDrug interactions of clinical importance with antihyperg-lycaemic agents: An updateDrug Saf200528760163115963007
- NeuvonenPJDrug interactions with HMG-CoA reductase inhibitors (statins): The importance of CYP enzymes, transporters and pharmacogeneticsCurr Opin Investig Drugs2010113323332
- HaslamISJonesKColemanTSimmonsNLInduction of P-glycoprotein expression and function in human intestinal epithelial cells (T84)Biochem Pharmacol200876785086118703021
- KhaliqYGallicanoKVenanceSKravcikSCameronDWEffect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virusClin Pharmacol Ther200068663764611180024
- DeFronzoRHissaMNGarberAJOnce-daily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with type 2 diabetes [abstract]Diabetes200958 Suppl 1A147
- ZhangLBoultonDWPfisterMExposure modeling of saxagliptin and 5-hydroxy saxagliptin in healthy subjects and in patients with type 2 diabetes to support saxagliptin dosing recommendations [abstract]Diabetes201059Suppl 1A184
- NeuvonenPJNiemiMBackmanJTDrug interactions with lipid-lowering drugs: Mechanisms and clinical relevanceClin Pharmacol Ther200680656558117178259
- ZhouSYungCSCherGBMechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugsClin Pharmacokinet200544327930415762770